These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
664 related articles for article (PubMed ID: 30905548)
21. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P Cells; 2020 Mar; 9(3):. PubMed ID: 32168869 [TBL] [Abstract][Full Text] [Related]
22. Medical treatment for cholangiocarcinoma. Adeva J; Sangro B; Salati M; Edeline J; La Casta A; Bittoni A; Berardi R; Bruix J; Valle JW Liver Int; 2019 May; 39 Suppl 1():123-142. PubMed ID: 30892822 [TBL] [Abstract][Full Text] [Related]
23. Current and emerging therapies for advanced biliary tract cancers. Kam AE; Masood A; Shroff RT Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563 [TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies. Alsina M; Moehler M; Lorenzen S Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786 [TBL] [Abstract][Full Text] [Related]
25. Infigratinib in patients with advanced cholangiocarcinoma with Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579 [TBL] [Abstract][Full Text] [Related]
26. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Rizzo A; Ricci AD; Brandi G Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004 [TBL] [Abstract][Full Text] [Related]
31. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. Brown ZJ; Ruff SM; Pawlik TM Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395 [TBL] [Abstract][Full Text] [Related]
32. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382 [TBL] [Abstract][Full Text] [Related]
33. [Medical management of cholangiocarcinomas in 2015]. Marret G; Neuzillet C; Rousseau B; Tournigand C Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666 [TBL] [Abstract][Full Text] [Related]
34. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. Jensen LH; Jakobsen A Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326 [TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Blair AB; Murphy A Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212 [TBL] [Abstract][Full Text] [Related]
38. Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. Tariq NU; Vogel A; McNamara MG; Valle JW Oncol Res Treat; 2018; 41(5):298-304. PubMed ID: 29705791 [TBL] [Abstract][Full Text] [Related]